<DOC>
	<DOCNO>NCT02394730</DOCNO>
	<brief_summary>ADVICE randomise , international , double-blind , placebo-controlled trial . The purpose ADVICE study compare safety efficacy vorapaxar reduce d-dimer expression marker cellular immune activation period 12 week among people HIV infection successfully treat combination antiretroviral therapy contain HIV integrase inhibitor . A secondary objective study demonstrate follow cessation vorapaxar patient well control HIV replication increase level d-dimer 6 week period . 60 participant 4 clinical site Australia USA recruit follow minimum 18 week .</brief_summary>
	<brief_title>Attenuation D-dimer Using Vorapaxar Target Inflammatory Coagulation Endpoints</brief_title>
	<detailed_description>Consenting participant screen within 14 day randomly allocate receive either vorapaxar ( 2.5mg ) match placebo daily 12 week ( phase 1 ) . Participants see one week randomisation week 4 , 8 12 ( phase 1 ) . At week 12 visit , patient dispense study treatment . In phase 2 study treatment stop 6 week . At week 18 patient see final study visit .</detailed_description>
	<mesh_term>Vorapaxar</mesh_term>
	<criteria>1 . HIV1 positive license diagnostic test 2. age ≥40 year 3. plasma HIV RNA &lt; 50 copies/mL least 24 week 4. screen CD4+ cell count &gt; 50 cells/mm3 5. treat least 12 week suppressive regimen combination antiretroviral therapy include HIV protease inhibitor and/or NNRTIs ( except rilpivirine ) 6. plasma ddimer &gt; 200ng/mL ( &gt; 0.2μg/mL &gt; 0.2mg/L ) fibrinogen equivalent unit &gt; 100ng/mL ( &gt; 0.1 μg/mL &gt; 0.1mg/L ) ddimer unit absence establish cause ( deep vein thrombosis/embolism ) 7. provision write informed consent 1 . Absolute neutrophil count ( ANC ) &lt; 1000 cells/μL 2. hemoglobin &lt; 10.0 g/dL 3. platelet count &lt; 75,000 cells/μL 4 . AST and/or ALT &gt; 2.5 x ULN 5. estimate glomerular filtration rate &lt; 30mL/min/1.73m2 ) use CKDEPI ( Chronic Kidney Disease Epidemiology Collaboration ) equation 6. history myocardial infarction unstable atherosclerotic disease 7. history ischemic stroke transient ischaemic attack ( TIA ) 8. active peptic/duodenal ulcer bleed disorder within previous 12 month 9. intent surgery within 6 month period randomisation 10. current use aspirin P2Y12 antiplatelet therapy 11. use anticoagulant , ( eg . heparin warfarin ) , fibrinolytic therapy , chronic use ( 5 consecutive day ) nonsteroidal antiinflammatory drug ( NSAIDS ) , strong CYP3A4 inhibitor inducer . See Manual Operations full list medication avoid . 12. participant unlikely able remain followup 13. pregnant nursing mother 14. clinical judgement investigator , participation trial deem inappropriate may conflict wellbeing participant .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>HIV , d-dimer , hs-CRP , activate T-lymphocytes</keyword>
</DOC>